ATE227305T1 - Protease hemmende peptide und peptid-analogen - Google Patents
Protease hemmende peptide und peptid-analogenInfo
- Publication number
- ATE227305T1 ATE227305T1 AT96902650T AT96902650T ATE227305T1 AT E227305 T1 ATE227305 T1 AT E227305T1 AT 96902650 T AT96902650 T AT 96902650T AT 96902650 T AT96902650 T AT 96902650T AT E227305 T1 ATE227305 T1 AT E227305T1
- Authority
- AT
- Austria
- Prior art keywords
- butyl
- compounds
- iso
- peptide analogues
- protease inhibiting
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 3
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical group CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 229910052799 carbon Chemical group 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Chemical group CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 150000004799 α-ketoamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/369,422 US5804560A (en) | 1995-01-06 | 1995-01-06 | Peptide and peptide analog protease inhibitors |
| PCT/US1996/000359 WO1996020949A1 (en) | 1995-01-06 | 1996-01-05 | Peptide and peptide analog protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227305T1 true ATE227305T1 (de) | 2002-11-15 |
Family
ID=23455418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96902650T ATE227305T1 (de) | 1995-01-06 | 1996-01-05 | Protease hemmende peptide und peptid-analogen |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US5804560A (de) |
| EP (1) | EP0800528B1 (de) |
| JP (1) | JPH11514330A (de) |
| AT (1) | ATE227305T1 (de) |
| AU (1) | AU4697296A (de) |
| CA (1) | CA2209234A1 (de) |
| DE (1) | DE69624681T2 (de) |
| DK (1) | DK0800528T3 (de) |
| ES (1) | ES2184850T3 (de) |
| PT (1) | PT800528E (de) |
| WO (1) | WO1996020949A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849711A (en) * | 1995-06-06 | 1998-12-15 | Athena Neurosciences, Inc. | Cathepsin and methods and compositions for inhibition thereof |
| AR016751A1 (es) * | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
| US6191166B1 (en) | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6211235B1 (en) | 1996-11-22 | 2001-04-03 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6207710B1 (en) | 1996-11-22 | 2001-03-27 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
| WO1999062880A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| AU762373B2 (en) * | 1998-10-20 | 2003-06-26 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
| US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| WO2000051998A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6649593B1 (en) * | 1999-10-13 | 2003-11-18 | Tularik Inc. | Modulators of SREBP processing |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
| US6358928B1 (en) | 1999-11-22 | 2002-03-19 | Enzyme Systems Products | Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases |
| EP1244670B1 (de) | 1999-12-21 | 2006-03-08 | MGI GP, Inc. | Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung |
| GB0003111D0 (en) | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| JP2003528071A (ja) * | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| JP4666440B2 (ja) * | 2000-06-30 | 2011-04-06 | 生化学工業株式会社 | アミノアルコール誘導体 |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| EP2289888A3 (de) * | 2000-06-30 | 2011-07-13 | Seikagaku Corporation | Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit |
| JP2004502665A (ja) * | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| EP1315971A2 (de) * | 2000-07-31 | 2003-06-04 | The Regents of The University of California | Modell für alzheimer und neurodegenerative krankheiten |
| CA2420186C (en) * | 2000-08-21 | 2007-05-15 | The General Hospital Corporation | Methods for diagnosing a neurodegenerative condition |
| US20040192889A1 (en) * | 2001-03-30 | 2004-09-30 | Dale Bredesen | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| US6982263B2 (en) * | 2001-06-08 | 2006-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitriles useful as reversible inhibitors of cysteine proteases |
| WO2003002122A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
| WO2003072037A2 (en) * | 2002-02-27 | 2003-09-04 | Pharmacia & Upjohn Company | High-level production of amyloid-beta peptides from imr-32 cells |
| JP4511805B2 (ja) * | 2002-04-26 | 2010-07-28 | 武田薬品工業株式会社 | ネプリライシンの活性測定法 |
| WO2003105677A2 (en) * | 2002-06-01 | 2003-12-24 | Praecis Pharmaceuticals, Inc. | Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation |
| AU2003256305A1 (en) * | 2002-06-24 | 2004-01-06 | Axys Pharmaceuticals, Inc. | Peptidic compounds as cysteine protease inhibitors |
| US20070172453A1 (en) * | 2002-08-30 | 2007-07-26 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| EP1633786A4 (de) * | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus |
| CA2543884A1 (en) | 2003-10-30 | 2005-05-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Dipeptide-analogue synthesis |
| US7544855B2 (en) * | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| WO2013148554A1 (en) * | 2012-03-30 | 2013-10-03 | Merck Sharp & Dohme Corp. | Process for preparing fluoroleucine alkyl esters |
| BR112014028094B1 (pt) | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2024018245A1 (en) | 2022-07-22 | 2024-01-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of calpain inhibitors for the treatment of the diabetic kidney disease |
| WO2024153744A1 (en) | 2023-01-20 | 2024-07-25 | Institut National de la Santé et de la Recherche Médicale | Autophagy activators for the treatment of rhabdomyolysis |
| CN116239513B (zh) * | 2023-05-05 | 2023-08-18 | 天津凯莱英制药有限公司 | Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) * | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| CA1161431A (en) * | 1979-05-11 | 1984-01-31 | Lars G. Svendsen | Tripeptide derivatives |
| FR2477801A1 (fr) * | 1980-03-05 | 1981-09-11 | Thomson Csf | Procede de modulation de phase par un signal binaire et dispositif mettant en oeuvre ce procede |
| US4423029A (en) * | 1981-06-25 | 1983-12-27 | The Procter & Gamble Company | (S)-3-Amino-4-[(S,S)-1-(1-hydroxyethyl)alkyl amino]-4-oxo-butyric acid compounds suitable as non-nutritive sweetners |
| US4701407A (en) * | 1982-11-24 | 1987-10-20 | Baylor College Of Medicine | Diagnosis of Alzheimer disease |
| US4472305A (en) * | 1983-05-17 | 1984-09-18 | Sterling Drug Inc. | Hexapeptide amides |
| US4845079A (en) * | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| FR2585708B1 (fr) * | 1985-07-31 | 1989-07-07 | Sanofi Sa | Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique |
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US4829052A (en) * | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
| US5034376A (en) * | 1986-10-31 | 1991-07-23 | Pfizer Inc. | Nor-statine and nor-cyclostatine polypeptides |
| MY103189A (en) * | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
| EP0274826B1 (de) * | 1986-11-17 | 1998-08-12 | Scios Inc. | Rekombiniertes Alzheimer Amyloid-Protein |
| DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
| JPS63245689A (ja) * | 1987-03-31 | 1988-10-12 | Suntory Ltd | ヒトアミロイド関連蛋白モノクロ−ナル抗体 |
| JPS63290858A (ja) * | 1987-04-08 | 1988-11-28 | サルター・インコーポレーテツド | アミロイド症及びアルツハイマー病の診断分析法及びそのための試薬 |
| US5039511A (en) * | 1987-04-08 | 1991-08-13 | Salutar, Inc. | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
| GB8809316D0 (en) * | 1987-05-11 | 1988-05-25 | Ici America Inc | Heterocyclic ketones |
| US5547841A (en) * | 1987-10-08 | 1996-08-20 | The Mclean Hospital Corporation | In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid |
| US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US5015570A (en) * | 1988-05-13 | 1991-05-14 | Molecular Therapeutics, Inc. | Molecular diagnosis of Alzheimer Disease |
| DE3833572A1 (de) * | 1988-10-03 | 1990-04-05 | Pfersee Chem Fab | Stabile, feinteilige, waessrige einkomponenten-silikonkatalysatoren, verfahren zu deren herstellung und deren verwendung |
| ZA897515B (en) * | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
| WO1990005138A1 (en) * | 1988-11-08 | 1990-05-17 | The Children's Medical Center Corporation | Cytotoxic amyloid precursors and screening assays using them |
| US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
| JPH07116223B2 (ja) * | 1989-04-07 | 1995-12-13 | 宇部興産株式会社 | 新規なトリペプチドおよびその用途 |
| JP2701932B2 (ja) * | 1989-04-10 | 1998-01-21 | サントリー株式会社 | タンパク質分解酵素阻害剤 |
| WO1990012871A1 (en) * | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
| US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
| US5232928A (en) * | 1989-07-25 | 1993-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tetrahydroisoquinoline amides |
| CA2021660A1 (en) * | 1989-07-26 | 1991-01-27 | Philippe Bey | Peptidase inhibitors |
| JPH05502368A (ja) * | 1989-09-18 | 1993-04-28 | サイオス ノバ インコーポレイテッド | アミロイド沈着物の測定法および試薬 |
| US5221665A (en) * | 1989-10-27 | 1993-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | N-substituted amides |
| AU7121191A (en) * | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
| GB9007922D0 (en) * | 1990-04-07 | 1990-06-06 | Oxford Virology Plc | A diagnostic test method |
| US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
| CA2079880A1 (en) * | 1990-04-24 | 1991-10-25 | William E. Van Nostrand | Purification, detection and methods of use of protease nexin-2 |
| US5284828A (en) * | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| US5430022A (en) * | 1990-05-14 | 1995-07-04 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound and its preparation |
| US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| CA2043741C (en) * | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
| US5496928A (en) * | 1990-06-07 | 1996-03-05 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
| WO1992000521A1 (en) * | 1990-06-29 | 1992-01-09 | Case Western Reserve University | Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor |
| US5223633A (en) * | 1990-06-30 | 1993-06-29 | Bayer Aktiengesellschaft | Preparation of sec. or tert. alcohols |
| US5200339A (en) * | 1990-08-17 | 1993-04-06 | Abraham Carmela R | Proteases causing abnormal degradation of amyloid β-protein precursor |
| WO1992003542A1 (en) * | 1990-08-17 | 1992-03-05 | Boston University | PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID β-PROTEIN PRECURSOR |
| US5292652A (en) * | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
| WO1992007065A1 (en) * | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
| BE1003316A5 (fr) * | 1990-11-27 | 1992-02-25 | Will L F & Cie Sa | Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation. |
| US5444042A (en) * | 1990-12-28 | 1995-08-22 | Cortex Pharmaceuticals | Method of treatment of neurodegeneration with calpain inhibitors |
| EP0572547A1 (de) * | 1991-02-22 | 1993-12-08 | The Du Pont Merck Pharmaceutical Company | Substituierte alpha-amino aldehyde und derivate |
| EP0504938A3 (en) * | 1991-03-22 | 1993-04-14 | Suntory Limited | Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient |
| ATE181925T1 (de) * | 1991-05-23 | 1999-07-15 | Merrell Pharma Inc | Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau |
| CA2075771A1 (en) * | 1991-08-12 | 1993-02-13 | Paul Van Eikeren | Enzymatic synthesis of renin inhibitors |
| WO1993007296A1 (en) * | 1991-10-03 | 1993-04-15 | Indiana University Foundation | Method for screening for alzheimer's disease |
| EP0613560B2 (de) * | 1991-11-12 | 2006-06-21 | Prana Biotechnology Ltd | Verfahren zur bestimmung und behandlung von alzheimer-krankheit |
| JPH05140063A (ja) * | 1991-11-19 | 1993-06-08 | Suntory Ltd | ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤 |
| US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
| AU679675B2 (en) * | 1992-05-11 | 1997-07-10 | Bayer Corporation | Methods for detecting beta amyloid precursor protein processing enzymes |
| WO1995013084A1 (en) * | 1992-05-11 | 1995-05-18 | Miles Inc. | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
| JPH05345754A (ja) * | 1992-06-15 | 1993-12-27 | Suntory Ltd | ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤 |
| EP0650368A1 (de) * | 1992-06-24 | 1995-05-03 | Cortex Pharmaceuticals, Inc. | Verwendung von calpain inhibitoren in der inhibition und behandlung von medizinischen zuständen die mit einer erhöhten calpainaktivität assoziiert sind |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| WO1994001772A1 (en) * | 1992-07-13 | 1994-01-20 | The Children's Medical Center Corporation | SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION |
| ATE173088T1 (de) * | 1992-07-22 | 1998-11-15 | Mclean Hospital Corp | Verfahren zum nachweis von alzheimer-krankheit |
| EP0580161A1 (de) * | 1992-07-22 | 1994-01-26 | THE McLEAN HOSPITAL CORPORATION | Prophylaktische und therapeutische Behandlung der Alzheimer'schen Krankheit |
| US5374623A (en) * | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
| WO1994009370A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors |
| WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| WO1994009155A1 (en) * | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| US5605811A (en) * | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
| WO1994013798A1 (en) * | 1992-12-16 | 1994-06-23 | Bergmann Johanna E | Agents for the prevention and treatment of human alzheimer's disease |
| WO1994019692A1 (en) * | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| CA2115900A1 (en) * | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| US5538997A (en) * | 1993-03-12 | 1996-07-23 | Sandoz Ltd. | 2,4-diamino-3-hydroxycarboxylic acid derivatives |
| NZ262447A (en) * | 1993-03-16 | 1996-07-26 | British Biotech Pharm | Hydroxamic acid derivatives and their use as pharmaceutical agents |
| DK1564293T3 (da) * | 1993-04-20 | 2009-01-12 | Gen Hospital Corp | Nervetrådproteingenekspression og detektion af Alzheimers sygdom |
| JP3599287B2 (ja) * | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | スルホンアミド誘導体 |
| CA2122227A1 (en) * | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
| JPH0789951A (ja) * | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−１β転換酵素阻害剤 |
| JPH06345722A (ja) * | 1993-06-04 | 1994-12-20 | Mitsubishi Kasei Corp | チオアセタール誘導体 |
| EP0627400A1 (de) * | 1993-06-04 | 1994-12-07 | Merrell Dow Pharmaceuticals Inc. | Aromatische Inhibitoren von Acetylcholinesterase |
| US5541290A (en) * | 1993-06-24 | 1996-07-30 | Harbeson; Scott L. | Optically pure calpain inhibitor compounds |
| GB9313330D0 (en) * | 1993-06-28 | 1993-08-11 | Fujisawa Pharmaceutical Co | New compound and its preparation |
| NZ264143A (en) * | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| US5866545A (en) * | 1993-08-13 | 1999-02-02 | Merck & Co., Inc. | Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme |
| HUT73527A (en) * | 1993-08-13 | 1996-08-28 | Seikagaku Kogyo Co Ltd | Remedy for nervous diseases |
| BR9407415A (pt) * | 1993-09-07 | 1996-11-12 | Procter & Gamble | Composições contendo um sal de aminoácido de agente antiinflamatório não-esteróide de ácido propiônico e caféina |
| DE4331134A1 (de) * | 1993-09-14 | 1995-03-16 | Bayer Ag | Neue antiviral wirksame Pseudopeptide |
| AU687449B2 (en) * | 1993-10-01 | 1998-02-26 | Aventis Inc. | Inhibitors of beta-amyloid protein production |
| DE69525145T2 (de) * | 1994-02-09 | 2002-08-29 | SHIONOGI & CO., LTD. | Carbamoylmethylharnstoffderivate |
| GB9402680D0 (en) * | 1994-02-11 | 1994-04-06 | Zeneca Ltd | Pyrrolidine derivatives |
| US5436229A (en) * | 1994-03-04 | 1995-07-25 | Eli Lilly And Company | Bisulfite adducts of arginine aldehydes |
| US5693617A (en) * | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| JP2540728B2 (ja) * | 1994-03-31 | 1996-10-09 | 株式会社脳機能研究所 | 脳活動自動判定装置 |
| US5643726A (en) * | 1994-11-10 | 1997-07-01 | The General Hospital Corporation | Methods for modulating transcription from the amyloid β-protein precursor (APP) promoter |
-
1995
- 1995-01-06 US US08/369,422 patent/US5804560A/en not_active Expired - Lifetime
- 1995-03-13 US US08/403,420 patent/US5969100A/en not_active Expired - Fee Related
- 1995-05-17 US US08/442,786 patent/US6051684A/en not_active Expired - Fee Related
- 1995-05-17 US US08/443,901 patent/US5714471A/en not_active Expired - Fee Related
- 1995-05-17 US US08/442,514 patent/US5962419A/en not_active Expired - Fee Related
- 1995-05-17 US US08/443,048 patent/US6153171A/en not_active Expired - Fee Related
- 1995-05-17 US US08/442,662 patent/US6015879A/en not_active Expired - Fee Related
-
1996
- 1996-01-05 WO PCT/US1996/000359 patent/WO1996020949A1/en not_active Ceased
- 1996-01-05 CA CA002209234A patent/CA2209234A1/en not_active Abandoned
- 1996-01-05 DK DK96902650T patent/DK0800528T3/da active
- 1996-01-05 EP EP96902650A patent/EP0800528B1/de not_active Expired - Lifetime
- 1996-01-05 JP JP8521271A patent/JPH11514330A/ja not_active Withdrawn
- 1996-01-05 ES ES96902650T patent/ES2184850T3/es not_active Expired - Lifetime
- 1996-01-05 AU AU46972/96A patent/AU4697296A/en not_active Abandoned
- 1996-01-05 AT AT96902650T patent/ATE227305T1/de not_active IP Right Cessation
- 1996-01-05 DE DE69624681T patent/DE69624681T2/de not_active Expired - Fee Related
- 1996-01-05 PT PT96902650T patent/PT800528E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69624681D1 (de) | 2002-12-12 |
| EP0800528B1 (de) | 2002-11-06 |
| EP0800528A1 (de) | 1997-10-15 |
| US6051684A (en) | 2000-04-18 |
| US6153171A (en) | 2000-11-28 |
| US5969100A (en) | 1999-10-19 |
| US5804560A (en) | 1998-09-08 |
| PT800528E (pt) | 2003-02-28 |
| US5962419A (en) | 1999-10-05 |
| AU4697296A (en) | 1996-07-24 |
| US6015879A (en) | 2000-01-18 |
| JPH11514330A (ja) | 1999-12-07 |
| WO1996020949A1 (en) | 1996-07-11 |
| CA2209234A1 (en) | 1996-07-11 |
| DK0800528T3 (da) | 2002-11-25 |
| US5714471A (en) | 1998-02-03 |
| ES2184850T3 (es) | 2003-04-16 |
| DE69624681T2 (de) | 2003-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69624681D1 (de) | Protease hemmende peptide und peptid-analogen | |
| WO1996020725A3 (en) | Peptide, peptide analog and amino acid analog protease inhibitors | |
| DE69334250D1 (de) | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern | |
| ATE241998T1 (de) | Multikatalytische protease-inhibitoren | |
| FI892067A0 (fi) | Gabapentinmonohydrat och foerfarande foer framstaellning daerav. | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ITRM920919A1 (it) | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale | |
| CA2081970A1 (en) | Hiv protease inhibitors useful for the treatment of aids | |
| IT8721618A0 (it) | Prodecimento per la depurazione bilogica di acque reflue. | |
| AP9200410A0 (en) | Retroviral protease inhibitors. | |
| ATE206110T1 (de) | Zns-aktive semicarbazone und diese enthaltende pharmazeutische zubereitungen | |
| RU94035686A (ru) | 4-ариламино-бензопиран и родственные соединения, фармацевтическая композиция, способ лечения | |
| ATE263761T1 (de) | 5,6-dihydropyronderivate als proteaseinhibitoren und antiviralmittel | |
| DE69313872D1 (de) | Verbindung von nucleocidanaloga zur behandlung viraler infektionen | |
| EP0832075A4 (de) | Neue n-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amiden | |
| ATE256667T1 (de) | Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen | |
| DE60231825D1 (de) | Behandlung von infektionen verursacht von mikroorganismen | |
| HRP940936B1 (en) | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | |
| EP0689455A4 (de) | Therapeutische strategieen bei infektionen mit immuninfizierendem clustervirus | |
| ATE208765T1 (de) | 2-amino-benzoxazinone zur behandlung von viralen infektionen | |
| ES2194102T3 (es) | Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
| DE69735039D1 (de) | Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen | |
| UA26459C2 (uk) | Іhгібітор впливу амілоїдhих білків | |
| DE69315730D1 (de) | Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu | |
| EP0723454A4 (de) | Für die immun- und cns-therapir nutzbare, neuartige tripeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0800528 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |